Mayzent (siponimod) prior authorization for multiple sclerosis
Defines prior authorization requirements, medical necessity criteria, covered indications, exclusions, prescriber specialization, approval durations, and appendix of other MS disease-modifying therapies for Mayzent (siponimod) for Cigna-administered health benefit plans.
Review Date updated to 07/23/2025 with Early Annual Revision noted; no criteria changes stated in history.
Coverage Summary
Overview: This policy defines prior authorization requirements and medical necessity criteria for Mayzent (siponimod) for relapsing forms of multiple sclerosis. The coverage stance is covered with criteria for FDA‑approved relapsing MS indications. Status: CURRENT. Effective/last review date: 07/23/2025.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.